Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J Moran

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Clinical Genitourinary Cancer|December 2, 2011
Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancerJonathan E Rosenberg, Ming-Hui Chen, Paul L Nguyen, et al.
JAMA Oncology|November 20, 2018
Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of MortalityDerya Tilki, Ming-Hui Chen, Jing Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk diseaseAnthony V D'Amico, Brian J Moran, Michelle H Braccioforte, et al.
Brachytherapy|September 11, 2008
Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory GroupWilliam S Bice, Bradley R Prestidge, Steven M Kurtzman, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapyAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
European Urology|September 18, 2012
Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery diseaseAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|September 12, 2009
Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapyAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
Brachytherapy|March 30, 2010
The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statementArthur K Cheung, Ming-Hui Chen, Brian J Moran, et al.
Cancer|March 24, 2010
Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancerKaren E Hoffman, Ming-Hui Chen, Brian J Moran, et al.
The Journal of Urology|October 25, 2011
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapyTimur Mitin, Ming-Hui Chen, Yuanye Zhang, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Clinical Genitourinary Cancer|December 2, 2011
Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancerJonathan E Rosenberg, Ming-Hui Chen, Paul L Nguyen, et al.
JAMA Oncology|November 20, 2018
Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of MortalityDerya Tilki, Ming-Hui Chen, Jing Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk diseaseAnthony V D'Amico, Brian J Moran, Michelle H Braccioforte, et al.
Brachytherapy|September 11, 2008
Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory GroupWilliam S Bice, Bradley R Prestidge, Steven M Kurtzman, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapyAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
European Urology|September 18, 2012
Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery diseaseAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|September 12, 2009
Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapyAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
Brachytherapy|March 30, 2010
The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statementArthur K Cheung, Ming-Hui Chen, Brian J Moran, et al.
Cancer|March 24, 2010
Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancerKaren E Hoffman, Ming-Hui Chen, Brian J Moran, et al.
The Journal of Urology|October 25, 2011
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapyTimur Mitin, Ming-Hui Chen, Yuanye Zhang, et al.
Pageof 6